Related by context. All words. (Click for frequent words.) 80 dose escalation study 77 Phase 1b 76 Phase 2b trial 76 Phase Ib 76 dose escalation Phase 76 Phase 2b study 75 Phase 1b clinical 75 Phase 1b trial 74 Phase Ib clinical 74 phase Ib 74 dose escalation 74 Phase Ib II 74 single ascending dose 74 dose escalation clinical 74 Phase 2a clinical 73 Phase 2a trial 73 multiple ascending dose 73 placebo controlled Phase 73 multicenter Phase 73 Phase Ib study 73 randomized Phase 72 label dose escalation 72 pivotal Phase III 71 Phase IIa trial 71 IIa trial 71 randomized Phase III 71 Phase IIa clinical 71 ascending dose 71 multicenter Phase II 71 Phase IIb 71 Phase III clinical 71 pivotal Phase 71 phase IIb 71 phase IIb clinical 71 Phase IIa 71 Phase Ia 71 phase IIa clinical 71 Phase 2a 70 Phase 2b clinical 70 randomized placebo controlled 70 BRIM2 70 placebo controlled 70 Phase 1a 70 randomized controlled Phase 70 dose cohorts 70 Phase III randomized 70 pharmacokinetics PK 69 double blind placebo 69 Phase 2b 69 phase IIa 69 blind randomized placebo 69 Phase IIb clinical 69 safety tolerability pharmacokinetics 69 randomized multicenter 69 Phase IIb trial 69 multicenter randomized placebo controlled 69 phase 2a 69 phase IIb study 69 Phase Ib clinical trials 68 tolerated dose MTD 68 ongoing Phase 1b 68 Phase #b/#a 68 multicenter randomized double 68 oral deforolimus 68 multicentre randomized 68 randomized double 68 placebo controlled clinical 68 Phase III 68 alvespimycin 68 double blinded placebo 68 dose dose escalation 68 oral ridaforolimus 68 Phase IIIb 68 Phase IIIb clinical 68 IIa clinical trial 68 LUX Lung 67 Phase III pivotal 67 treatment naive genotype 67 ascending doses 67 forodesine 67 multicenter clinical 67 clinical trial 67 pharmacokinetic PK study 67 TMC# C# 67 Phase #/#a 67 BRIM3 67 multicenter phase 67 multicenter randomized 67 confirmatory Phase III 67 safety tolerability 66 ADVANCE PD 66 HGS ETR1 66 phase IIb trial 66 safety tolerability pharmacokinetic 66 rALLy clinical trial 66 blinded randomized placebo controlled 66 relapsed refractory multiple myeloma 66 randomized controlled 66 SUCCEED trial 66 tolerability 66 double blinded randomized 66 axitinib 66 placebo controlled randomized 66 Phase 2b randomized 66 pharmacokinetic PK 66 IMGN# 66 PF # [001] 66 Cloretazine R VNP#M 66 controlled multicenter 65 CR# vcMMAE 65 masked placebo controlled 65 Phase II 65 ganetespib 65 label multicenter 65 Phase IIb trials 65 blind randomized 65 viral kinetic 65 dose cohort 65 Dacogen injection 65 placebo controlled Phase III 65 placebo controlled dose escalation 65 prospective multicenter 65 registrational trial 65 randomized Phase IIb 65 multicentre 65 pharmacodynamic profile 65 pharmacodynamics 65 dose regimens 65 Phase III randomized controlled 65 Phase #b/#a trial 65 JAK inhibitor 65 phase Ib clinical 65 NO# [002] 65 prospective randomized controlled 65 multicenter randomized controlled 65 registrational 65 Phase 1a clinical 65 prospective randomized 65 EOquin TM 65 multicenter Phase III 65 Sorafenib HCC Assessment 65 TG MV 65 HGS# 64 ofatumumab 64 Amrubicin 64 Sym# 64 Phase III placebo controlled 64 Phase IIa trials 64 treatment naïve genotype 64 Initiated Phase 64 nab paclitaxel 64 controlled dose escalation 64 multicenter 64 neratinib 64 HCV SPRINT 64 mertansine 64 Phase III clinical trials 64 XL# SAR# 64 huN# DM1 64 blind placebo controlled 64 Phase 1b clinical trials 64 blinded placebo controlled 64 INCB# [001] 64 RG# [001] 64 huC# DM4 64 active comparator 64 ABSORB trial 64 phase IIIb 63 sequential dose escalation 63 teriflunomide 63 PRECiSE 63 YONDELIS 63 evaluating tivozanib 63 pertuzumab 63 CTA# Injection 63 multicenter placebo controlled 63 tanespimycin 63 SCH # 63 rNAPc2 63 lorvotuzumab mertansine 63 multicentre randomized double 63 enzastaurin 63 dosing cohorts 63 IIa clinical 63 Phase #b/#a clinical 63 trastuzumab emtansine T DM1 63 PRE SURGE 63 randomized discontinuation trial 63 ANCHOR trial 63 pharmacokinetic profile 63 Phase 63 PSMA ADC 63 randomized Phase 2b 63 PEG PAL 63 oral prodrug 63 maximally tolerated dose 63 galiximab 63 randomized clinical 63 multicenter randomized Phase 63 pomalidomide 63 phase IIb III 63 dosing cohort 63 AIR CF1 63 Phase 1b dose escalation 63 lintuzumab SGN 63 intermittent dosing 63 GRN#L 63 administered subcutaneously 63 assessing T DM1 63 prospective multicenter randomized 63 refractory CLL 63 DermaVir Patch 62 mapatumumab 62 PDX pralatrexate 62 pharmacokinetic 62 Phase IIIb study 62 NP2 Enkephalin 62 PXD# 62 Phase IIb clinical trials 62 randomized controlled clinical 62 multicenter prospective 62 docetaxel Taxotere R 62 telaprevir dosing 62 Phase Ib IIa 62 COMFORT II 62 ABSORB clinical 62 Bezielle 62 ascending dose study 62 R#/MEM # 62 ZACTIMA 62 HCD# [002] 62 Traficet EN 62 HuMax CD4 62 ZYBRESTAT fosbretabulin 62 prospective randomized placebo 62 elotuzumab 62 GAMMAGARD 62 APTIVUS 62 randomized 62 II Clinical Trial 62 randomized controlled multicenter 62 GetGoal Phase III 62 docetaxel chemotherapy 62 pharmacodynamic effects 62 IMC A# 62 relapsed multiple myeloma 62 glufosfamide 62 registrational Phase 62 FOLOTYN ® 62 ORMD 62 REG2 62 subcutaneous formulation 62 HuMax EGFr 62 Initiate Phase 62 sorafenib Nexavar 62 pharmacokinetic studies 62 Randomized Phase 62 Phase 2b clinical trials 62 adecatumumab 62 HER2 positive metastatic breast 62 randomized multicenter trial 62 Allovectin 7 ® 62 perifosine 62 Sapacitabine 62 OncoVEX GM CSF 62 pharmacodynamics PD 62 cannabinor 62 sunitinib malate 62 dosing regimens 62 sorafenib Nexavar ® 62 AIR CF2 62 Aplidin 62 histone deacetylase HDAC inhibitor 62 EDEMA3 62 dose escalation phase 62 initiate Phase 1b 62 deforolimus 62 TG# [001] 62 randomized multicentre 62 mg/m2 dose 62 ENDEAVOR IV 62 Phase III multicenter 62 Carfilzomib 62 mg/m2 cohort 61 subcutaneous SC 61 NOX E# 61 VICTOR E1 61 Quinamed 61 AP# [003] 61 VNP#M 61 Phase III confirmatory 61 AQ4N 61 APEX PD 61 Maximum Tolerated Dose MTD 61 imetelstat GRN#L 61 blind multicenter 61 PSN# [002] 61 evaluating Vectibix 61 APPRAISE 61 Aflibercept 61 CEQ# 61 Cloretazine ® 61 oral rivaroxaban 61 PD LID 61 AEG# 61 evaluable patients 61 vicriviroc 61 azilsartan medoxomil 61 ILLUMINATE 61 Phase 2b kidney transplant 61 unique alkylating agent 61 Tarceva TM 61 GLP toxicology studies 61 investigational oral 61 BAY #-# 61 MEND CABG 61 crizotinib PF # 61 SABCS 61 ELACYT 61 desvenlafaxine succinate 61 nitazoxanide 61 confirmatory Phase 3 61 ROCKET AF 61 pharmacodynamic PD 61 AVADO 61 RE SURGE 61 label multicenter randomized 61 pharmacokinetic pharmacodynamic 61 elacytarabine 61 Augment Injectable 61 Panzem R NCD 61 IMA# 61 ALN VSP Phase 61 initiated Phase Ib 61 IMPACT DCM 61 carboplatin paclitaxel 61 Alocrest 61 INCB# [002] 61 TMC# [002] 61 Phase III trials 61 Azedra 61 prospective randomized multicenter 61 preclinical efficacy 61 DASISION 61 Vicinium TM 61 NCCTG 61 AIR CF3 61 TELCYTA 61 fosbretabulin 61 Imprime PGG 61 obatoclax 61 label multicenter Phase 61 Annamycin 61 budesonide foam 61 rALLy trial 61 ThermoDox R 61 ritonavir boosted 61 TACI Ig 61 European Sepsis Trial 61 SPIRIT FIRST 61 capecitabine Xeloda R 61 lintuzumab 61 XL# [003] 61 Enzastaurin 61 NSABP 61 noninferiority 61 Phase III VISTA 61 CHAMPION PCI 61 Alzhemed TM 61 PEG SN# 61 Omacetaxine 61 evaluating T DM1 61 CRLX# 61 solithromycin 61 randomized crossover 61 #mg QD [002] 61 velafermin 61 RSD# oral 60 antibody MAb 60 blind randomized controlled 60 LibiGel Phase III 60 AEGR 60 confirmatory clinical 60 bevirimat Study 60 SYMMETRY trial 60 lixisenatide 60 Phase IIB 60 randomized #:# 60 PRTX 60 NVA# 60 Blinatumomab 60 telaprevir dosed 60 PRIMO CABG 60 relapsed MM 60 generation PNP inhibitor 60 ThermoDox ® 60 Exherin TM 60 tgAAC# 60 Phase 2b monotherapy 60 velafermin belinostat 60 lead Aganocide compound 60 Phase #/#a trial 60 CLARITY study 60 CYT# 60 blinded randomized 60 controlled multicenter Phase 60 acyclovir Lauriad R 60 GALNS 60 CIMZIA TM 60 Kahalalide F 60 eniluracil 60 cathepsin K inhibitor 60 metastatic hormone refractory 60 initiate Phase IIb 60 rindopepimut 60 INSPIRE Trial Phase III 60 MEND CABG II 60 subcutaneous PRO 60 virus HCV protease inhibitor 60 VEGFR2 inhibitor 60 recurrent glioma 60 trastuzumab DM1 T DM1 60 SAR# [004] 60 tolerability pharmacokinetics 60 MAA submission 60 PROSTVAC ® 60 imetelstat 60 resminostat 60 initiate Phase 60 Urocidin 60 erlotinib Tarceva ® 60 BR.# 60 pharmacokinetic parameters 60 generation Hsp# inhibitor 60 ENESTnd 60 thorough QT 60 mGluR5 negative 60 CA4P 60 oral methylnaltrexone 60 Virulizin ® 60 Androxal TM 60 refractory multiple myeloma 60 3 registrational trial 60 OMP #M# 60 Fx #A 60 placebo controlled multicenter 60 HGS ETR2 60 IIa trials 60 PROSTVAC TM 60 orally bioavailable 60 RG# ITMN 60 REVIVE Diabetes 60 Phenoptin 60 MEK inhibitor 60 preclinically 60 MAGE A3 ASCI 60 Oral NKTR 60 teduglutide 60 Pharmacokinetics PK 60 CLL8 60 Aplidin R 60 unblinding 60 depsipeptide 60 humanized anti 60 tesmilifene 60 monotherapy 60 Parkinson disease levodopa induced 60 blinatumomab 60 ZD# [001] 60 Dose escalation 60 mg dose 60 LEVADEX 60 IL# PE#QQR 60 hypoxia activated prodrug 60 dasatinib Sprycel ® 60 mcg kg 60 pivotal bioequivalence 60 mg administered orally 60 PS# [001] 60 EVEREST II 60 investigational humanized monoclonal antibody 60 Randomized Phase II 59 #I TM# 59 liposomal formulation 59 docetaxel 59 paclitaxel poliglumex 59 Plicera 59 Phase III psoriasis 59 μg dose 59 aflibercept 59 temozolomide 59 trastuzumab Herceptin R 59 cilengitide 59 cell lymphoma CTCL 59 EORTC 59 tremelimumab 59 pharmacokinetics 59 evaluating Xcytrin 59 dyskinesia PD LID 59 mCRC 59 Pivotal Phase 59 GRNVAC1 59 ARDIS 59 dose limiting toxicities 59 MGCD# [001] 59 Phase IIb III 59 Glufosfamide 59 sNDA submission 59 metastatic HRPC 59 ToGA 59 Cloretazine 59 satraplatin Phase 59 mg QD 59 carfilzomib 59 decitabine 59 KRN# 59 PRESEPT 59 BCIRG 59 anti leukemic 59 multicenter study 59 TAXUS ATLAS 59 unblinded 59 Laquinimod 59 Tyrima 59 MIRCERA 59 intratumoural 59 MEK inhibitor RDEA# 59 FOLFOX6 chemotherapy regimen 59 antitumor activity 59 midstage trials 59 Phase #/#a clinical 59 ruxolitinib 59 TBC# 59 albiglutide 59 MGd 59 mg BID 59 non nucleoside inhibitor 59 brivaracetam 59 relapsing remitting multiple sclerosis 59 torezolid phosphate 59 Tanespimycin 59 LCP AtorFen 59 CALGB 59 ORAL Sync 59 nonrandomized 59 Phase III Clinical Trial 59 multicenter multinational 59 leading oral taxane 59 ixabepilone 59 randomized multicenter Phase III 59 RCW breast cancer 59 farletuzumab 59 FAME Study 59 sorafenib tablets 59 placebo controlled studies 59 Ozarelix 59 pazopanib 59 investigational compound 59 aflibercept VEGF Trap 59 BiTE R 59 PEG Interferon lambda 59 PRT# 59 GLPG# 59 Multimeric 59 dose regimen 59 posaconazole 59 TORISEL 59 mitogen activated ERK kinase 59 Combination REOLYSIN R 59 PANVAC VF 59 Dual Opioid 59 refractory metastatic colorectal cancer 59 cediranib 59 IPX# 59 nonclinical studies 59 Ophena TM 59 HCV RESPOND 2 59 Folfox 59 Ceplene/IL-2 59 RDEA# 59 Proxinium TM 59 davunetide intranasal AL 59 immunogenicity 59 standard chemotherapy regimen 59 FOLOTYN 59 CANCIDAS 59 edoxaban 59 oral sapacitabine 59 MT# MEDI 59 receptor tyrosine kinase inhibitor 59 entinostat 59 metastatic castrate resistant 59 eculizumab 59 visilizumab 59 thymalfasin 59 DEB# 59 CoFactor 59 systemic RNAi therapeutic 59 NGX# 59 albinterferon alfa 2b 59 Diamyd ® 59 T DM1 59 TMC# [001] 59 Archexin 59 peginterferon alfa 2b 59 AAG geldanamycin analog 59 Phase III Pivotal 59 recurrent malignant glioma 59 ARIKACE 59 prospective observational 59 sunitinib 59 LCP Tacro 59 cetrorelix 59 Amigal 59 evaluating mipomersen 59 Pralatrexate 59 PRIMO CABG2 59 Omacetaxine mepesuccinate 59 de novo kidney transplant 59 dacetuzumab SGN 59 PDE4 inhibitor 59 ZK EPO 59 Phase IIa proof 59 multicenter dose escalation 59 DB# [003] 59 null responder HCV 59 ENMD # 59 randomized blinded 59 AZILECT R 59 ACTEMRA TM 59 AERAS-#/Crucell Ad# 59 TAXUS IV 58 Hsp# Inhibitor 58 Prostate Lung Colorectal 58 dosage regimens 58 nucleotide analog 58 prostate cancer mCRPC 58 ExTRACT TIMI 58 Phase IIb Trial 58 mcg dose 58 adecatumumab MT# 58 Phase 2a clinical trials 58 Reolysin 58 Pivotal Trial 58 ocular formulation 58 pegylated interferon alfa 2a 58 Bayer HealthCare Onyx Pharmaceuticals 58 Zybrestat 58 Pivotal Phase III 58 midstage clinical 58 AKT inhibitor 58 Vascular Disrupting Agent 58 icatibant 58 TLK# 58 perifosine KRX 58 Dose Escalation 58 docetaxel Taxotere ® 58 metastatic castration resistant 58 romidepsin 58 KRAS mutations occur 58 CCR5 mAb 58 opioid induced bowel dysfunction 58 afatinib 58 Actilon 58 L BLP# 58 EOquin 58 Darusentan 58 LymphoStat B TM 58 randomized controlled clinical trials 58 subcutaneous methylnaltrexone 58 Kinesin Spindle Protein KSP 58 Triapine 58 MT#/MEDI-# 58 investigational pan BCR 58 vascular disrupting agent 58 gemcitabine 58 Dapagliflozin 58 bicifadine 58 Prostate AdenoCarcinoma Treatment 58 TASKi2 58 eltrombopag 58 Phase IIb randomized 58 immunotherapeutic agent 58 ILUVIEN ® 58 brivanib 58 lubiprostone 58 peginesatide 58 Prodarsan 58 HCV NS5B polymerase 58 Phase IIa clinical trials 58 melphalan prednisone 58 metaglidasen 58 pralatrexate 58 APOPTONE 58 zanolimumab 58 dependent kinase inhibitor 58 trabectedin 58 RANK Ligand inhibitor 58 OPT CHF 58 Safinamide 58 #mg/m# [002] 58 AVE# 58 Luteinizing Hormone Releasing Hormone 58 novel histone deacetylase 58 trastuzumab DM1 58 volociximab 58 Aryplase 58 CCR5 antagonist 58 evaluating REVLIMID 58 Betaferon ® 58 relapsed refractory AML 58 stage IIIB 58 sapacitabine 58 antiviral activity 58 Telatinib 58 vidofludimus 58 CALGB # [002] 58 clofarabine 58 EmbraceAC 58 PARTNER Trial 58 generation purine nucleoside 58 subcutaneously administered 58 ISIS # 58 RE LY 58 intravenous dosing 58 XIENCE V Stent System 58 ASSERT trial 58 IDX# 58 clinical trials 58 pitavastatin 58 SRT# [003] 58 temsirolimus 58 chemotherapy FOLFOX 58 phase III ACCLAIM 58 tolerability profile 58 observer blinded randomized 58 TRO# 58 clinical trials SGN 58 NSABP B 58 designated HVTN 58 GVAX 58 label dose titration 58 Testosterone MDTS ® 58 Medidur TM FA 58 MabCampath 58 indibulin 58 REOLYSIN ® 58 stated Michelle Berrey 58 intravenous belinostat 58 pan HDAC inhibitor 58 acute PAO 58 bendamustine 58 Phase III metastatic melanoma 58 metastatic renal cell carcinoma 58 Perifosine 58 pegylated interferon alpha 58 inhibitor RG# 58 pramlintide 58 #mg/m# [001] 58 CLORETAZINE TM VNP#M 58 OMP #R# 58 comparing alemtuzumab 58 Capesaris 58 Dose Ranging Study 58 fluticasone furoate 58 SPIRIT III 58 lomitapide 58 symptomatic BPH 58 Cotara 58 metastatic sarcomas 58 OvaRex ® MAb 58 heavily pretreated 58 metastatic colorectal carcinoma 58 PreCISe 58 selective androgen receptor modulator 58 ozarelix 58 OncoVex 58 Gattex 58 randomized #:#:# 58 Chemophase 58 mg/m2 58 viral kinetics 58 lesinurad 58 orally dosed 58 Pivotal Study 58 OHR/AVR# 58 Allovectin 7 58 tolevamer 58 humanized monoclonal antibody 58 celgosivir 58 NEO3 58 recurrent glioblastoma multiforme 58 XL# XL# XL# 58 CML CP 58 efficacy 58 Clinical Study 58 anticancer compound 58 Phase III ALLEGRO 58 multiple myeloma MM 58 cancer neuroendocrine tumor 58 CAMMS# 58 FOLFIRI chemotherapy 58 ularitide 58 clinical pharmacology studies 58 polymerase inhibitor 58 Phase 2b Clinical Trial 58 Matrix Phase 2b 58 NXL# 58 urocortin 2 58 DU #b 58 bapineuzumab AAB 58 iniparib 58 Diabetic Macular Edema DME 58 methylnaltrexone 58 HPTN 58 Ophena 58 dalbavancin 58 Velcade bortezomib 58 investigational drug 58 pegylated liposomal doxorubicin 58 Engerix B 58 evaluating Actimmune 58 Ixempra 58 RECORD1 58 DAVANAT 57 relapsing multiple sclerosis 57 prospective nonrandomized 57 pharmacokinetic profiles 57 glatiramer acetate 57 riociguat 57 PROMACTA 57 CRx 57 refractory cutaneous T 57 AZOR 57 RGB # 57 CCX# 57 Seliciclib 57 angiogenesis inhibitor 57 compound INCB# 57 multicenter randomized clinical 57 TG# [003] 57 EchoCRT 57 MLN# 57 M Vax 57 Efficacy Results 57 intravenous bolus 57 leukemia AML 57 CTAP# Capsules 57 NCIC CTG 57 BrachySil 57 PF # [002] 57 HGS ETR1 mapatumumab 57 ZYBRESTAT 57 miconazole Lauriad ® 57 telomerase inhibitor drug 57 Targretin 57 ISENTRESS 57 varespladib 57 irbesartan 57 trodusquemine 57 Aurora kinase inhibitor 57 bortezomib Velcade R 57 EMPHASIS HF trial 57 dose pharmacokinetic 57 unresectable Stage III 57 PROPEL 57 MVax 57 pain palliation 57 sipuleucel T 57 CB2 selective receptor agonist 57 blind placebo 57 Phase lll 57 Board DSMB 57 RE LY ® 57 fostamatinib 57 Zenvia Phase III 57 IMP# 57 HQK 57 novel VDA molecule 57 unblind 57 Phase IIA 57 Allovectin 7 R 57 VEGF Trap 57 Aeroquin 57 PRX # 57 vinorelbine 57 PHX# 57 amrubicin 57 GOUT 57 GW# [003] 57 PI3K/Akt pathway inhibitor 57 hA# 57 DLTs 57 Q#IR 57 HspE7 57 Alpharadin 57 NOXAFIL Oral Suspension 57 Taxotere R 57 CONSERV 57 dirucotide 57 telaprevir VX 57 advanced carcinoid 57 severe oral mucositis 57 Tesetaxel 57 plus gemcitabine 57 dacetuzumab 57 papillary renal cell carcinoma 57 JANUVIA 57 Aurexis 57 Clolar 57 ORACLE MS 57 Genasense oblimersen sodium Injection 57 CRMD# 57 budesonide MMX 57 subcutaneous dose 57 BrachySil TM 57 APTIVUS r 57 REVLIMID lenalidomide 57 BRAF inhibitor 57 CUSTOM III 57 Aclidinium 57 belinostat 57 ACTEMRA 57 relapsed CLL 57 Pegasys plus Copegus 57 IND submission 57 plus dexamethasone 57 COU AA 57 JAK2 inhibitor 57 Locteron ® 57 VELCADE melphalan 57 Ostarine 57 sodium thiosulfate STS 57 RIBBON 57 TAXUS VI 57 Study Evaluating 57 bevacizumab Avastin ® 57 Clinical Oncology Annual Meeting 57 PEGylated interferon beta 1a 57 Myocet 57 recurrent NSCLC 57 mg/m2/day 57 HRPC 57 BCX# 57 nucleoside analog 57 SUTENT ® 57 platinum refractory 57 non inferiority 57 omacetaxine mepesuccinate 57 vandetanib 57 ocular hypertension 57 tramiprosate Alzhemed TM 57 5 fluorouracil leucovorin 57 prospectively randomized 57 demonstrated antitumor activity 57 mCRC patients 57 PNP inhibitor 57 cariprazine 57 sunitinib Sutent 57 interferon gamma 1b 57 CBLC# 57 samalizumab 57 ASCO abstract 57 gemcitabine carboplatin 57 EFAPROXYN 57 MORAb 57 Neuradiab 57 OXi# 57 trial evaluating PRX# 57 refractory acute myeloid 57 pharmacodynamic properties 57 #th Annual Interscience 57 q8h 57 valopicitabine 57 investigational protease inhibitor 57 veltuzumab 57 palifosfamide Zymafos TM 57 clinical trials Multikine 57 fidaxomicin Phase 3 57 cutaneous T cell 57 antibody MT# 57 ThermoDox 57 IRX 2 57 sodium glucose cotransporter 57 refractory chronic lymphocytic 57 initiate Phase Ib 57 DSMB 57 motesanib 57 sorafenib 57 VITAL Trial 57 pharmacodynamic 57 NLX P# 57 BLA submission 57 eprotirome 57 recurrent metastatic ovarian cancer 57 injectable formulation 57 plus prednisone 57 MDV# 57 XL# XL# XL# XL#